ULTRAGENYX PHARMACEUTICAL INC. - COMMON STOCK

Ultragenyx Announces Upcoming Data Presentations at American Society of Gene & Cell Therapy (ASGCT) 2022 Annual Meeting

09 May 2022 08:00:01 By Nasdaq GlobeNewswire

Ultragenyx Reports First Quarter 2022 Financial Results and Corporate Update

05 May 2022 16:05:02 By Nasdaq GlobeNewswire

Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

03 May 2022 17:00:00 By Nasdaq GlobeNewswire

Ultragenyx to Participate at BofA Securities 2022 Healthcare Conference

03 May 2022 16:05:01 By Nasdaq GlobeNewswire

Ultragenyx to Host Conference Call for First Quarter 2022 Financial Results and Corporate Update

27 Apr 2022 16:01:00 By Nasdaq GlobeNewswire

Ultragenyx Issues Inaugural Environmental, Social and Governance (ESG) Report

25 Apr 2022 13:18:09 By Nasdaq GlobeNewswire

Ultragenyx Appoints Amrit Ray, M.D., M.B.A. to Board of Directors

22 Apr 2022 08:00:00 By Nasdaq GlobeNewswire

Ultragenyx Announces First Patient Dosed in Pivotal Phase 2/3 Clinical Study of Setrusumab (UX143) for the Treatment of Osteogenesis Imperfecta

20 Apr 2022 08:00:01 By Nasdaq GlobeNewswire

Ultragenyx to Participate in the Cowen Health Care Conference

02 Mar 2022 16:01:00 By Nasdaq GlobeNewswire

Ultragenyx Reports Fourth Quarter and Full Year 2021 Financial Results and Corporate Update

10 Feb 2022 16:05:01 By Nasdaq GlobeNewswire

Ultragenyx to Host Conference Call for Fourth Quarter and Full-Year 2021 Financial Results and Corporate Update

03 Feb 2022 16:01:00 By Nasdaq GlobeNewswire

Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

02 Feb 2022 16:05:00 By Nasdaq GlobeNewswire

Ultragenyx Reports Preliminary 2021 Revenue and 2022 Revenue Guidance for Crysvita® in Ultragenyx Territories* And Dojolvi® Globally; Provides Pipeline Updates and 2022 Milestones

10 Jan 2022 08:00:02 By Nasdaq GlobeNewswire

Ultragenyx to Present at H.C. Wainwright BioConnect Healthcare Conference

06 Jan 2022 16:01:00 By Nasdaq GlobeNewswire

GeneTx and Ultragenyx Provide Preliminary Update on Phase 1/2 Clinical Study of GTX-102 in Canada and U.K. Patients with Angelman Syndrome

05 Jan 2022 08:00:01 By Nasdaq GlobeNewswire

Ultragenyx to Present at 40th Annual JP Morgan Healthcare Conference

03 Jan 2022 16:01:00 By Nasdaq GlobeNewswire

GeneTx and Ultragenyx Announce Presentations at Upcoming 2021 FAST Global Summit & Gala

01 Dec 2021 16:30:00 By Nasdaq GlobeNewswire

Ultragenyx Announces First Patient Dosed in Phase 1/2 Clinical Study of UX053, an mRNA Therapy for the Treatment of Glycogen Storage Disease Type III

01 Dec 2021 08:00:01 By Nasdaq GlobeNewswire

Ultragenyx to Present at Evercore 4th Annual HealthconX Conference

29 Nov 2021 16:40:38 By Nasdaq GlobeNewswire

Ultragenyx Announces Additional Positive Multi-Year Durability Data from Phase 1/2 AAV Gene Therapy Studies

29 Nov 2021 08:00:00 By Nasdaq GlobeNewswire